This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce
by Zacks Equity Research
Kezar (KZR) falls 10% on the decision to channel resources to one clinical candidate as part of its reprioritization efforts and slash the workforce by 41%.
Wall Street Analysts See an 82% Upside in Kezar Life Sciences, Inc. (KZR): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Kezar Life Sciences, Inc. (KZR) points to an 81.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Biotech ETF Tops in June: 5 Stocks That Outperform
by Sweta Killa
Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bargain hunting.
Wall Street Analysts Think Kezar Life Sciences, Inc. (KZR) Could Surge 135%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 135.4% in Kezar Life Sciences, Inc. (KZR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More
by Zacks Equity Research
Regulatory and other updates from Epizyme (MRNA) and Kezar (KZR) are a few key highlights from the biotech sector during the past week.
Kezar (KZR) Doubles on Promising Kidney Disorder Study Data
by Zacks Equity Research
Shares of Kezar (KZR) surge more than 100% during after-hour trading on Jun 27, following a promising data readout from a mid-stage study evaluating zetomipzomib in patients with active lupus nephritis.
Down 10.7% in 4 Weeks, Here's Why Kezar Life Sciences, Inc. (KZR) Looks Ripe for a Turnaround
by Zacks Equity Research
Kezar Life Sciences, Inc. (KZR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Is IQ Chaikin U.S. Small Cap ETF (CSML) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for CSML
Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CSML
Kezar Life Sciences, Inc. (KZR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Kezar Life Sciences, Inc. (KZR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
After Plunging 59.3% in 4 Weeks, Here's Why the Trend Might Reverse for Kezar Life Sciences, Inc. (KZR)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Kezar Life Sciences, Inc. (KZR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Should You Buy Kezar (KZR) Ahead of Earnings?
by Zacks Equity Research
Kezar (KZR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Earnings Season Could Be Great for Kezar Life Sciences (KZR)
by Zacks Equity Research
Kezar Life Sciences (KZR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Top Ranked Momentum Stocks to Buy for May 11th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 11th
Is Kezar Life Sciences (KZR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (KZR) Outperforming Other Medical Stocks This Year?